Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828768 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13828773 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13717897 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13828879 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13829008 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13828882 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13828980 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13828875 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13829006 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB | |
| SCHEMBL13828877 | 1.00 | TSHR (0.46) | TSHRALDH1A1CYP3A4LSSTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150786-B2 | Polymerizable monomer compound, liquid crystal composition, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20120286201-A1 | POLYMERIZABLE MONOMER COMPUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120286201-A1 | POLYMERIZABLE MONOMER COMPUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | MBD2, CCND1, MBTD1 | TSHR 4007/4885ALDH1A1 2819/4885CYP3A4 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.